Skip to content
DraconiticResearch
Search Sources API
210,089 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NC 4.0The Science of Diabetes Self-Management and Care

Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry

  • Kathleen A. Willoughby1
  • Huyen T. Nguyen1
  • Katherine S. Chapman1
  • Megan E. Peter1
  • Grazia Aleppo2
  • Wendy A. Wolf1
  1. 1T1D Exchange, Inc, Boston, MA, USA
  2. 2Northwestern University, Chicago, IL, USA
Read full textDOICite

Abstract

Purpose:: The purpose of this study was to (1) describe characteristics of people who have used inhaled insulin (Afrezza), (2) explore their experiences with obtaining and using inhaled insulin, and (3) assess perceived impacts of inhaled insulin on quality of life (QoL) related to diabetes management.

Methods:: A cross-sectional survey was collected from adults with type 1 diabetes (T1D) or latent autoimmune diabetes (LADA) who currently use or previously used inhaled insulin. Participants were recruited from the T1D Exchange Registry. All participants responded to survey questions regarding their experiences with inhaled insulin; responses were compared between current and past users using Welch’s t tests or were summarized using descriptive statistics.

Results:: The sample included 151 respondents (89 current users and 62 past users), most of whom used a continuous glucose monitor (96%) and self-reported an A1C <7% (77%). On a 5-point scale, the most important consideration for continuation of inhaled insulin reported among current users was perceived effectiveness in lowering glucose levels (M = 4.8), while the most important consideration for discontinuation among past users was the out-of-pocket cost (M = 3.4). Using a 5-point Likert scale, overall QoL ratings were higher (mean difference = 0.8, 95% CI, 0.61.0]) among current users (M = 4.3) compared with past users (M = 3.5).

Conclusions:: In a real-world sample of people with T1D and LADA, current users felt that Afrezza positively impacted their daily lives. Still, barriers to access remain. Efforts to reduce financial and obtainment obstacles may support broader use of inhaled insulin.

Related

  1. Experiences of People with Type 2 Diabetes and Healthcare Professionals with Once-Weekly Insulin Efsitora Alfa in QWINT Phase 3 Trials: Qualitative In-Trial Interviews
    William H. Polonsky, Emma L. Low, Carla Dias-Barbosa +9
    The PatientPeer-reviewedCC BY-NC 4.0Full textEndocrinology & metabolismPMC
  2. Concentrated growth factor in combination with insulin for improving type 2 diabetes mellitus alveolar bone regeneration: a pilot study
    Huiru Li, Chennan Shi, Luyan Xing +9
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  3. Distinct insulin sensitivity profiles revealed by clustering based on continuous glucose monitoring data in people living with type 1 diabetes
    Svjatoslavs Kistkins, Anastasija Luganceva, Sergejs Lobanovs +8
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
  4. Impact of type 2 diabetes mellitus in patients with congenital heart disease (CHD): a study from the Australian National CHD Registry.
    Larissa Lloyd, Calum Nicholson, Geoff Strange +1
    BMJ open diabetes research & carePeer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMC
  5. Association Between the Relative Duration of Sliding Scale Insulin Use and the Length of Hospital Stay in Non-Critically Ill Patients with Type 2 Diabetes
    Hanna Osawa, Kelechi Obi, Mahbubur Rahman +1
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{willoughby2026experiences,
  title = {{Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry}},
  author = {Kathleen A. Willoughby and Huyen T. Nguyen and Katherine S. Chapman and Megan E. Peter and Grazia Aleppo and Wendy A. Wolf},
  journal = {The Science of Diabetes Self-Management and Care},
  year = {2026},
  month = sep,
  doi = {10.1177/26350106261475926},
  url = {https://doi.org/10.1177/26350106261475926},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry
AU  - Kathleen A. Willoughby
AU  - Huyen T. Nguyen
AU  - Katherine S. Chapman
AU  - Megan E. Peter
AU  - Grazia Aleppo
AU  - Wendy A. Wolf
PY  - 2026
DA  - 2026/09/07
JO  - The Science of Diabetes Self-Management and Care
DO  - 10.1177/26350106261475926
UR  - https://doi.org/10.1177/26350106261475926
AB  - Purpose:: The purpose of this study was to (1) describe characteristics of people who have used inhaled insulin (Afrezza), (2) explore their experiences with obtaining and using inhaled insulin, and (3) assess perceived impacts of inhaled insulin on quality of life (QoL) related to diabetes management.  Methods:: A cross-sectional survey was collected from adults with type 1 diabetes (T1D) or latent autoimmune diabetes (LADA) who currently use or previously used inhaled insulin. Participants were recruited from the T1D Exchange Registry. All participants responded to survey questions regarding their experiences with inhaled insulin; responses were compared between current and past users using Welch’s t tests or were summarized using descriptive statistics.  Results:: The sample included 151 respondents (89 current users and 62 past users), most of whom used a continuous glucose monitor (96%) and self-reported an A1C <7% (77%). On a 5-point scale, the most important consideration for continuation of inhaled insulin reported among current users was perceived effectiveness in lowering glucose levels (M = 4.8), while the most important consideration for discontinuation among past users was the out-of-pocket cost (M = 3.4). Using a 5-point Likert scale, overall QoL ratings were higher (mean difference = 0.8, 95% CI, 0.61.0]) among current users (M = 4.3) compared with past users (M = 3.5).  Conclusions:: In a real-world sample of people with T1D and LADA, current users felt that Afrezza positively impacted their daily lives. Still, barriers to access remain. Efforts to reduce financial and obtainment obstacles may support broader use of inhaled insulin.
SN  - 2635-0106
SN  - 2635-0114
ER  -